Working to Eradicate Gynecologic Cancers

101 -Featured Poster
Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

Monday, March 24, 2014: 7:24 AM
Room 13-16 (Tampa Convention Center)
T. J. Herzog1, G. E. Richardson2, B. J. Monk3, B. Y. Karlan4, C. Marth5, L. Navale6, D. J. Warner6 and A. M. Oza7
1Columbia University College of Physicians and Surgeons, New York, NY, 2Cabrini Hospital, Melbourne, Australia, 3University of Arizona Cancer Center, Phoenix, AZ, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5Medical University Innsbruck, Innsbruck, Austria, 6Amgen Inc., Thousand Oaks, CA, 7Princess Margaret Hospital, Toronto, ON, Canada
 
See more of: Featured Poster Session V: Clinical Trials/Drug Repurposing
See more of: Featured Poster Session
<< Previous Presentation | Next Presentation >>